

FIG. 1




FIG. 2A

Comparison of titers raised single epitopes versus dual epitope




FIG. 2B

Comparison of titers raised single epitopes versus dual epitope





FIG. 3A

Brain AD 04-33 - Vaccine Serum 2 – Dilution 1-300



Arrows: tau pathology


Arrowheads: A-beta pathology

Vaccine Serum 2: serum from vaccinated Guinea pig number 2

Immunogen 9 DAEFRHRRQIVYKPVGGC

FIG. 3B

Brain AD 04-33 - Vaccine Serum 2 – Dilution 1-300



Arrows: tau pathology


Arrowheads: A-beta pathology

Vaccine Serum 2: serum from vaccinated Guinea pig number 2

Immunogen 9 DAEFRHDDRQIVYKPVGGC

FIG. 3C

Brain AD 04-33 - Vaccine Serum 2 – Dilution 1-1500



Arrows: tau pathology

Arrowheads: A-beta pathology

Vaccine Serum 2: serum from vaccinated Guinea pig number 2

FIG. 3D

Brain AD 04-33 - Control Serum – Dilution 1-300



FIG. 3E

Brain AD 04-33 - Control Serum – Dilution 1-300




FIG. 3F

Brain AD 04-33 - Control Serum – Dilution 1-1500



FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B
Abeta and Tau titers using various linkers in dual immunogen




FIG. 6A
Immunogen 19 Mouse 1 – 1:1000 dilution




FIG. 6B
Immunogen 19 Mouse 3 – 1:1000 dilution




FIG. 6C

Negative Control - mouse serum – 1:1000 dilution






FIG. 6D


Positive Tau control - m6H3 Ab – 0.1 ug/ml



Tau pathology

FIG. 6E

REFERENCE: Guinea pig serum Immunogen 9
Vaccine GP # 2 – 1:300 dilution



A-beta →
Tau ➤

FIG. 7A




FIG. 7B




FIG. 8A

Titers over time of the four injection schedule 1




FIG. 8B

Titers over time of the three injection schedule 2




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10A




FIG. 10B

Weak Tau pathology




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B

No Tau pathology




FIG. 13

Final bleed of dual Abeta-Tau constructs





FIG. 14**Competition of tau by sera**

- ◆ DAEFRHDDR RVKSKIGSTGGC
- DAEFRHDDR RSKIGSTENGGC
- ★ DAEFRHDDR RTENLKHQPGGC
- ✱ DAEFRHDDR RENLKHQPGGGC
- ◇ DAEFRHDDR RSKIGSKDNIKHGGC
- Neg Control

FIG. 15A




FIG. 15B





FIG. 15C

Competition of tau by sera from DAEFRHDDRRTENLKHQPGGC construct

**FIG. 15D**

Competition of tau by sera from DAEFRHDDRRENLKHQPGGC construct




FIG. 15E

Competition of tau by sera from DAEFRHDRRSKIGSKDNIKHGGC construct




FIG. 15F

Controls on Heparin Plate




FIG. 15G

Competition of tau by sera from DAEFRHRRRSKIGSKDNIKHGGC construct





FIG. 16A



▲ Abeta pathology
➡ Tau pathology
(abundant in neurites)

Abeta/Tau Dual Vaccine Mouse Serum 2.3_031521 (1:300)
Example of staining with DAEFRHRRVKSKIGSTGC

FIG. 16B




FIG. 16C






FIG. 16D



▲ Abeta pathology
➡ Tau pathology
(abundant in neurites)

Abeta/Tau Dual Vaccine Mouse Serum 9.2_031521 (1:300)
Example of staining with DAEFRHDDRRENKHKQPGGC

FIG. 16E



▲ Abeta pathology
➡ Tau pathology
(abundant in neurites)

Abeta/Tau Dual Vaccine Mouse Serum 11.1_031521 (1:300)
Example of staining with DAEFRHRRRSKIGSKDNIKHGGC